# Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

> **NCT02914405** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital Southampton NHS Foundation Trust** · enrollment: 44 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ch14.18/CHO

## Key facts

- **NCT ID:** NCT02914405
- **Lead sponsor:** University Hospital Southampton NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-24
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914405, "Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02914405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*